Hims & Hers stock falls 10% on revenue miss

Hims & Hers stock falls 10% on revenue miss


The Hers app arranged on a smartphone in New York, US, on Wednesday, Feb. 12, 2025. 

Gabby Jones | Bloomberg | Getty Images

Shares of Hims & Hers Health fell 9% in extended trading on Monday after the telehealth company reported second-quarter results that missed Wall Street’s expectations for revenue.

Here’s how the company did based on average analysts’ estimates compiled by LSEG:

  • Earnings per share: 17 cents adjusted vs. 15 cents
  • Revenue: $544.8 million vs. $552 million

Revenue at Hims & Hers increased 73% in the second quarter from $315.6 million during the same period last year, according to a release. Hims & Hers reported a net income of $42.5 million, or 17 cents per share, compared to $13.3 million, or 6 cents per share, during the same period a year earlier.

For its third quarter, Hims & Hers said it expected to report revenue between $570 million to $590 million, while analysts were expecting $583 million. The company said its adjusted EBITDA for the quarter will be between the range of $60 million to $70 million. Analysts polled by StreetAccount were expecting $77.1 million.

Hims & Hers has faced controversy in recent months over its continued sale of compounded GLP-1s, which are cheaper, unapproved versions of the blockbuster diabetes and weight loss drugs. Compounded drugs can be mass produced when brand-name treatments are in shortage, but the U.S. Food and Drug Administration announced in February that ongoing supply issues had been resolved.

Some telehealth companies, including Hims & Hers, have continued to offer the compounded medications. It’s legal for patients to access personalized doses of the knockoffs in unique cases, like if they are allergic to an ingredient in a branded product, for instance. Hims & Hers has said consumers may still be able to access personalized doses through its site if clinically applicable. 

In June, Hims & Hers shares tumbled more than 30% after a short-lived collaboration with Novo Nordisk fell apart. The drugmaker said Hims & Hers “failed to adhere to the law which prohibits mass sales of compounded drugs” under the “false guise” of personalization.

Hims & Hers reported adjusted EBITDA of $82 million for its second quarter, up from $39.3 million last year and above the $73 million expected by StreetAccount.

Hims & Hers will host its quarterly call with investors at 5 p.m. ET.

Stock Chart IconStock chart icon

hide content

YTD chart of Hims & Hers Health.

–CNBC’s Annika Kim Constantino contributed to this report



Source

CNBC Daily Open: The White House might need a rebranding exercise in the corporate world
World

CNBC Daily Open: The White House might need a rebranding exercise in the corporate world

U.S. President Donald Trump looks on during the signing of executive orders in the Oval Office at the White House in Washington, D.C., on Aug. 25, 2025. Jonathan Ernst | Reuters “State-owned enterprise” is a term you wouldn’t normally bandy about when mentioning the United States — especially not with the country’s Republican party, which […]

Read More
CNBC Daily Open: U.S. wants equity in private businesses — staking its reputation
World

CNBC Daily Open: U.S. wants equity in private businesses — staking its reputation

U.S. President Donald Trump wears a ‘Trump Was Right About Everything!’ hat, in the Oval Office at the White House in Washington, D.C., U.S., August 22, 2025. Jonathan Ernst | Reuters “State-owned enterprise” is a term you wouldn’t normally bandy about when mentioning the United States — especially not with the country’s Republican party, which […]

Read More
Lutnick says update coming this week on Japan’s 0 billion U.S. investment
World

Lutnick says update coming this week on Japan’s $550 billion U.S. investment

The United States will make an announcement this week on Japan’s $550 billion investment in the U.S., Commerce Secretary Howard Lutnick said. Simon2579 | Digitalvision Vectors | Getty Images The United States will make an announcement this week on Japan’s $550 billion investment in the U.S., Commerce Secretary Howard Lutnick said, as a top Japanese trade envoy was reportedly planning to visit Washington to […]

Read More